decisionhealth Newsletters, Part B News - 2015 Issue 8 (August)
OIG opinion: Free cancer drug for patients through specialty pharmacy OK
Subscribe or sign in to view the full article.
Article Overview
This article covers an Office of Inspector General advisory opinion about a free medication supply program operated through a specialty pharmacy and a pharmaceutical company. It is relevant to compliance, pharmacy operations, oncology practices, and healthcare legal/regulatory readers who want to understand the broad concerns reviewed by OIG, including anti-kickback and beneficiary inducement issues, as well as the limited circumstances described in the opinion.
Why This Topic Matters
The piece matters because it shows how OIG evaluates patient assistance arrangements involving free drugs, specialty pharmacies, and insurer delays. Readers in compliance, pharmacy, and oncology settings can use it to understand the general regulatory issues that may affect similar programs.
What You Will Learn
- What the OIG advisory opinion addressed
- Why free-drug patient assistance programs can raise compliance concerns
- How specialty pharmacy arrangements intersect with federal fraud and abuse review
- What broad factors OIG considered in this specific program
- Why the opinion’s scope is limited to the facts presented
Who Should Read This
- Healthcare compliance professionals
- Pharmacy administrators
- Oncology practice managers
- Medical billing and reimbursement staff
- Healthcare attorneys
- Specialty pharmacy operators
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com